Inne

Inne provides a CE-certified, hormone-free contraception system based on saliva-based hormone monitoring, offering the first certified saliva-based alternative to the pill. The inne minilab consists of an inne reader and test strips that measure progesterone levels and cervical fluids from daily saliva samples, interpreting hormonal readings and sending them directly to the inne app via Bluetooth. The system achieves 92% effectiveness with typical use, comparable to condoms (87%) and approaching the pill (93%), while remaining completely hormone-free and requiring no prescription. Inne is IVDR-certified by Notified Body BSI (certificate IVDR 812439) since June 2025, with clinically proven results including up to 100% effectiveness under ideal conditions. The platform supports four use cases: natural contraception, conception planning, cycle-based living, and hormone understanding. Over 10,000 women already use inne as part of their routine, with subscription pricing from €21/month including the reader. The system offers a 30-day money-back guarantee with only 1% of customers utilizing it, and holds a 4.3/5 Trustpilot rating. Founded in 2018 and headquartered in Berlin, Germany, inne has raised $18.9M in Series A funding from investors including Blossom Capital, Monkfish Equity, Borski Fund, Calm/Storm, DSM, and Hornet Ventures.